(Q34408447)

2 August 2017

1 reference

title

Fluoroquinolone adverse effects and drug interactions (English)

1 reference

2 August 2017

Fish DN

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

21

1 reference

2 August 2017

issue

10 Pt 2

1 reference

2 August 2017

page(s)

253S-272S

1 reference

Safety profile of the quinolones

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Fluoroquinolone toxicity profiles: a review focusing on newer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Temafloxacin syndrome: review of 95 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Overview of fluoroquinolone safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Side-effects of quinolones: Comparisons between quinolones and other antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. The South Swedish Lolex Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Structure-activity and structure-side-effect relationships for the quinolone antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Tolerability of fluoroquinolone antibiotics. Past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Safety of intravenous ciprofloxacin. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

The chemistry and biological profile of trovafloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Clinical experience with ciprofloxacin in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Cutaneous photosensitivity diseases induced by exogenous agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Ciprofloxacin-induced neutropenia and erythema multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Ofloxacin-induced acute severe hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Enoxacin acute liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Acute renal failure due to ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

A reappraisal of quinolone tolerability. The experience of their musculoskeletal adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Quinolone arthropathy in animals versus children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

A case of destructive polyarthropathy in a 17-year-old youth following pefloxacin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use--safety report

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

More on fluoroquinolone antibiotics and tendon rupture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Fatal vasculitis associated with ofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Sucralfate reduces the gastrointestinal absorption of norfloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Pharmacokinetics and pharmacodynamics of newer fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Pharmacokinetic interactions related to the chemical structures of fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Enoxacin--a potent inhibitor of theophylline metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Involvement of inhibitory and excitatory neurotransmitters in levofloxacin- and ciprofloxacin-induced convulsions in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Interaction between phenytoin and ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Investigation of a possible interaction between ciprofloxacin and cyclosporine in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

The clinical pharmacokinetics of levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Pharmacokinetic interaction of sparfloxacin and digoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

Central nervous system toxicity of quinolones: human and animal findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.16.253S.33993

10.1592/PHCO.21.16.253S.33993

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference